


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:49:16Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12405237" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12405237</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>ejnmmires</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">EJNMMI Res</journal-id><journal-id journal-id-type="iso-abbrev">EJNMMI Res</journal-id><journal-id journal-id-type="pmc-domain-id">1625</journal-id><journal-id journal-id-type="pmc-domain">ejnmmires</journal-id><journal-title-group><journal-title>EJNMMI Research</journal-title></journal-title-group><issn pub-type="epub">2191-219X</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12405237</article-id><article-id pub-id-type="pmcid-ver">PMC12405237.1</article-id><article-id pub-id-type="pmcaid">12405237</article-id><article-id pub-id-type="pmcaiid">12405237</article-id><article-id pub-id-type="pmid">40892155</article-id><article-id pub-id-type="doi">10.1186/s13550-025-01306-7</article-id><article-id pub-id-type="publisher-id">1306</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Imaging renal mitochondrial dysfunction in chronic kidney disease: a repurposed role for [<sup>99m</sup>Tc]Tc-MIBI SPECT/CT</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3502-8818</contrib-id><name name-style="western"><surname>Park</surname><given-names initials="SB">Soo Bin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lim</surname><given-names initials="CH">Chae Hong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jin</surname><given-names initials="SY">So-Young</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="YH">Yon Hee</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="H">Haekyung</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="H">Hyoungnae</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Noh</surname><given-names initials="H">Hyunjin</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jeon</surname><given-names initials="JS">Jin Seok</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4114-4196</contrib-id><name name-style="western"><surname>Kwon</surname><given-names initials="SH">Soon Hyo</given-names></name><address><email>ksoonhyo@schmc.ac.kr</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03qjsrb10</institution-id><institution-id institution-id-type="GRID">grid.412674.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 1773 6524</institution-id><institution>Department of Nuclear Medicine, Soonchunhyang University Hospital, </institution><institution>Soonchunhyang University College of Medicine, </institution></institution-wrap>Seoul, Republic of Korea </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03qjsrb10</institution-id><institution-id institution-id-type="GRID">grid.412674.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 1773 6524</institution-id><institution>Department of Pathology, Soonchunhyang University Hospital, </institution><institution>Soonchunhyang University College of Medicine, </institution></institution-wrap>Seoul, Republic of Korea </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03qjsrb10</institution-id><institution-id institution-id-type="GRID">grid.412674.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 1773 6524</institution-id><institution>Division of Nephrology, Department of Internal Medicine, Soonchunhyang University Hospital, </institution><institution>Soonchunhyang University College of Medicine, </institution></institution-wrap>Seoul, Republic of Korea </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">479053</issue-id><elocation-id>115</elocation-id><history><date date-type="received"><day>1</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>8</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="13550_2025_Article_1306.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">[<sup>99m</sup>Tc]Tc-MIBI is a conventional myocardial perfusion radiotracer, and is predominantly taken up by mitochondria in a manner dependent on mitochondrial membrane potential. This study aimed to repurpose [<sup>99m</sup>Tc]Tc-MIBI for functional renal imaging to evaluate mitochondrial dysfunction in chronic kidney disease (CKD).</p></sec><sec><title>Results</title><p id="Par2">A total of 11 patients with newly diagnosed CKD and 27 matched healthy volunteers underwent [99mTc]Tc-MIBI dynamic renal scans and SPECT/CT. Quantitative analyses of the left kidneys assessed time-activity curves, percentage of renal uptake, and standardized uptake values (SUV). Renal mitochondrial content in CKD patients was evaluated using immunohistochemistry of kidney biopsy samples. CKD patients had comparable eGFR to healthy volunteers but exhibited significantly lower renal [<sup>99m</sup>Tc]Tc-MIBI uptake percentage on dynamic scan and decreased SUV on SPECT/CT. A positive correlation was observed between mean SUV and renal mitochondrial content in CKD patients. Mean SUV was identified as an independent predictor of CKD (odds ratio 0.2, <italic toggle="yes">P</italic>&#8201;=&#8201;0.037), demonstrating high diagnostic accuracy (AUC&#8201;=&#8201;0.886), whereas conventional biomarkers had limited predictive value.</p></sec><sec><title>Conclusions</title><p id="Par3">[<sup>99m</sup>Tc]Tc-MIBI kidney SPECT/CT effectively detected renal mitochondrial dysfunction in patients with CKD, suggests its potential as a noninvasive imaging biomarker. SUV may serve as a quantitative parameter for assessing renal mitochondrial dysfunction.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>SPECT/CT</kwd><kwd>Chronic kidney disease</kwd><kwd>[<sup>99m</sup>Tc]Tc-MIBI</kwd><kwd>MIBI</kwd><kwd>Mitochondrial dysfunction</kwd></kwd-group><funding-group><award-group><funding-source><institution>National Research Foundation of Korea</institution></funding-source><award-id>NRF-2020R1G1A1102033</award-id><award-id>NRF-2022R1A2C1007571</award-id><principal-award-recipient><name name-style="western"><surname>Park</surname><given-names>Soo Bin</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>Soon Hyo</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002560</institution-id><institution>Soonchunhyang University</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer-Verlag GmbH Germany, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par24">Chronic kidney disease (CKD) is defined as any sign of kidney damage or a glomerular filtration rate (GFR) of less than 60 mL/min for 3 months or more, regardless of cause [<xref ref-type="bibr" rid="CR1">1</xref>]. It is an increasing global problem, with an estimated approximately 700 million people suffering from CKD worldwide, imposing substantial socioeconomic costs [<xref ref-type="bibr" rid="CR2">2</xref>]. Early diagnosis and management are crucial to improving CKD outcomes. However, most patients are diagnosed at the later stages of the disease due to&#160;the asymptomatic nature of early to moderate CKD. Conventional biomarkers, particularly serum creatinine and urine albumin, are limited by poor sensitivity in detecting early kidney damage or predicting progression [<xref ref-type="bibr" rid="CR3">3</xref>&#8211;<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par25">Recently, mitochondrial dysfunction has emerged as an early and critical role in CKD pathogenesis, contributing to renal injury, inflammation and fibrotic responses [<xref ref-type="bibr" rid="CR8">8</xref>&#8211;<xref ref-type="bibr" rid="CR12">12</xref>]. This dysfunction is characterized by impaired mitochondrial bioenergetics, increased oxidative stress, and altered mitochondrial dynamics, all of which play crucial roles in the progression of CKD. Therefore, assessing renal mitochondrial function could facilitate earlier diagnosis and guide the development of targeted therapies in CKD [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. However, clinically efficient methods of evaluating renal mitochondrial dysfunction are currently lacking [<xref ref-type="bibr" rid="CR15">15</xref>&#8211;<xref ref-type="bibr" rid="CR17">17</xref>].</p><p id="Par26">Nuclear medicine (NM) renal imaging is a molecular imaging technique which offers non-invasive assessment of renal function in vivo [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Recently, a hybrid imaging with single photon emission computed tomography and computed tomography (SPECT/CT) has emerged and enables the quantification of localized renal radioactivity [<xref ref-type="bibr" rid="CR20">20</xref>]. While conventional radiotracers such as [<sup>99m</sup>Tc]TcDTPA<sup>2&#8722;</sup> (DTPA), allow for functional assessment of the kidneys, they are limited in their capacity for subclinical functional alterations [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par27">[<sup>99m</sup>Tc]Tc-MIBI (MIBI) is a widely used SPECT radiotracer for myocardial perfusion imaging that is taken up in cells mostly by mitochondria and whose retention is dependent on mitochondrial membrane potential [<xref ref-type="bibr" rid="CR23">23</xref>&#8211;<xref ref-type="bibr" rid="CR26">26</xref>]. MIBI has been applied to assess mitochondrial function in non-cardiac tissues [<xref ref-type="bibr" rid="CR27">27</xref>&#8211;<xref ref-type="bibr" rid="CR29">29</xref>]. However, its potential for evaluating renal mitochondrial function remains unexplored. Repurposing this well-established radiopharmaceutical could offer a cost-effective approach to mitochondrial imaging in CKD. Thus, we aimed to evaluate MIBI SPECT/CT for in vivo assessment of renal mitochondrial function in CKD patients, and to compare its diagnostic performance with conventional biomarkers.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Subjects</title><p id="Par28">We prospectively enrolled 11 patients who were undergoing initial diagnostic evaluation for newly diagnosed CKD at the Department of Nephrology of our institution from September 2020 to August 2022. All CKD cases were diagnosed histopathologically by kidney biopsy, except for one case of Alport syndrome diagnosed by DNA sequencing. As controls, 27 age, sex, and estimated GFR-matched healthy volunteers (HVs) were enrolled who had no known significant medical conditions, including diabetes and hypertension, and were not taking any medications. Furthermore, to confirm normal kidney function in the HVs, serum creatinine-based estimated GFR (eGFR<sub>SCr</sub>) calculated via the CKD Epidemiology Collaboration equation, routine urinalysis with sediment, and urine microalbumin/creatinine ratio in spot urine samples were analyzed. Additionally, a DTPA renal scan was performed. Subjects with structural renal abnormalities such as renal stones, hydronephrosis, or tumors identified on the CT component of the MIBI kidney SPECT/CT were excluded. Two subjects were excluded: one CKD patient, in whom a renal stone&#160;was detected, and one HV, in whom proteinuria and an abnormal DTPA dynamic renal scan were suggestive of mild kidney disease. Soonchunhyang University Hospital Review Board approved this study (No. 2020-07-017), and written informed consent was obtained from all participants. The current study was conducted in accordance with the ethical standards of the institutional and/or national research committee and the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.</p></sec><sec id="Sec4"><title>Dynamic renal imaging</title><p id="Par29">All subjects underwent both DTPA and MIBI renal dynamic planar scans within 30&#160;days. Imaging was acquired on a dedicated hybrid dual-head SPECT/CT scanner (Symbia Intevo, Siemens Medical Solutions, IL) using a low-energy high-resolution collimator. Renal dynamic scintigraphy was performed in the supine position following the bolus intravenous injection of 222&#160;MBq of DTPA or 555&#160;MBq of MIBI. The dynamic scans for DTPA or MIBI were acquired posteriorly at 2&#160;s/frame for 30 frames, followed by 15&#160;s/frame for 80 or 120 frames, respectively. Radioactivity was counted 60&#160;s on the pre- and post-injection syringes, and the net injection dose was then calculated.</p></sec><sec id="Sec5"><title>SPECT/CT acquisitions</title><p id="Par30">SPECT/CT was acquired serially following the completion of MIBI renal dynamic scan, starting approximately 35&#160;min after MIBI injection. The imaging field fully included both kidneys and the liver. SPECT was acquired at 64 stops per detector (angle of 2.813&#176;) at 20&#160;s/stop. CT was performed without using a contrast agent with a 16-slice helical CT scanner, and the images were reconstructed into 3&#160;mm slices (110&#160;kV, 80&#160;mA in the Auto-mA mode). CT-based attenuation-corrected quantitative SPECT was reconstructed on 256&#8201;&#215;&#8201;256 matrices using Flash 3D ordered subset expectation maximization and ordered subset conjugate gradient maximization (xSPECT Quant, Siemens Medical Solutions, IL) algorithms (8 subsets and 12 iterations; Gaussian filter of 8.0). Finally, the SPECT and CT images were co-registered to create fusion SPECT/CT images.</p></sec><sec id="Sec6"><title>Data processing of dynamic renal scans</title><p id="Par31">DTPA and MIBI renal dynamic scans were managed in accordance with clinical practice using commercially available software (Symbia.net, Siemens Medical Solutions, IL). For the scans, data processing and image analyses were conducted using images of the left kidney; the right kidney was excluded due to challenges in accurately delineating it from radioactivity in the small intestine caused by hepatobiliary excretion of MIBI. A region of interest (ROI) was automatically drawn to encompass the entirety of left renal activity and a crescent-shaped background ROI located in the inferior regions of the kidneys. A left renal time activity curve (TAC) was generated, and the corresponding time of maximum counts (T<sub>max</sub>) and half of maximum counts (T<sub>1/2</sub>) were extracted. A T<sub>1/2</sub> greater than 20&#160;min was considered indicative of delayed renal excretion. The percentage of renal uptake relative to the injected radioactivity dose (%ID<sub>2&#8211;3&#160;min</sub>) was automatically calculated from images acquired between 2 and 3&#160;min.</p><p id="Par32">On DTPA scans, GFR (GFR<sub>DTPA</sub>) was automatically calculated between 2 and 3&#160;min by the software using the Gates equation as follows: <inline-formula id="IEq1"><alternatives><tex-math id="d33e481">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$GFR\left( {{\text{ml}}/{\text{min}}} \right) = \left( {left\;kidney\;count - background\;count} \right)/e^{ - \mu x} \times 100 \times 9.81270 - 6.82519$$\end{document}</tex-math><mml:math id="d33e486"><mml:mrow><mml:mi>G</mml:mi><mml:mi>F</mml:mi><mml:mi>R</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mtext>ml</mml:mtext><mml:mo stretchy="false">/</mml:mo><mml:mtext>min</mml:mtext></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>t</mml:mi><mml:mspace width="0.277778em"/><mml:mi>k</mml:mi><mml:mi>i</mml:mi><mml:mi>d</mml:mi><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>y</mml:mi><mml:mspace width="0.277778em"/><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mo>-</mml:mo><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>k</mml:mi><mml:mi>g</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi><mml:mspace width="0.277778em"/><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo stretchy="false">/</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:mi>&#956;</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msup><mml:mo>&#215;</mml:mo><mml:mn>100</mml:mn><mml:mo>&#215;</mml:mo><mml:mn>9.81270</mml:mn><mml:mo>-</mml:mo><mml:mn>6.82519</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="13550_2025_1306_Article_IEq1.gif"/></alternatives></inline-formula>, with &#967; representing left kidney depth and &#181; representing the attenuation coefficient of <sup>99m</sup>Tc in soft tissue (0.153/cm). System-generated kidney depth was calculated using the following formula; <inline-formula id="IEq2"><alternatives><tex-math id="d33e556">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$left\;kidney\;depth\left( {{\text{cm}}} \right) = 13.2*\left( {\frac{weight}{{height}}} \right) + 0.7$$\end{document}</tex-math><mml:math id="d33e561"><mml:mrow><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>t</mml:mi><mml:mspace width="0.277778em"/><mml:mi>k</mml:mi><mml:mi>i</mml:mi><mml:mi>d</mml:mi><mml:mi>n</mml:mi><mml:mi>e</mml:mi><mml:mi>y</mml:mi><mml:mspace width="0.277778em"/><mml:mi>d</mml:mi><mml:mi>e</mml:mi><mml:mi>p</mml:mi><mml:mi>t</mml:mi><mml:mi>h</mml:mi><mml:mfenced close=")" open="("><mml:mtext>cm</mml:mtext></mml:mfenced><mml:mo>=</mml:mo><mml:mn>13.2</mml:mn><mml:mrow/><mml:mo>&#8727;</mml:mo><mml:mfenced close=")" open="("><mml:mfrac><mml:mrow><mml:mi mathvariant="italic">weight</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">height</mml:mi></mml:mrow></mml:mfrac></mml:mfenced><mml:mo>+</mml:mo><mml:mn>0.7</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="13550_2025_1306_Article_IEq2.gif"/></alternatives></inline-formula> [<xref ref-type="bibr" rid="CR30">30</xref>].</p></sec><sec id="Sec7"><title>SPECT/CT image analysis</title><p id="Par33">A nuclear medicine physician manually segmented the left kidney volume of interest (VOI) for each subject using the best-in-class contouring software (MIM version 7.0.7, MIM Software Inc, Cleveland, OH). The kidney VOI was confirmed by viewing axial, coronal, and sagittal images of SPECT, CT, and fusion SPECT/CT images simultaneously. Standardized uptake value (SUV) within the VOI was calculated as the ratio of radioactivity count to the injected dose divided by body weight. The maximum SUV (SUV<sub>max</sub>), mean SUV (SUV<sub>mean</sub>), and volume of the left kidney were recorded. To serve as a reference, a circular VOI with a diameter of 3&#160;cm was drawn in the right hepatic lobe, and the SUV<sub>mean</sub> for that VOI was calculated.</p></sec><sec id="Sec8"><title>Immunohistochemical analysis of renal mitochondrial content</title><p id="Par34">Renal biopsy samples were obtained from the CKD group within 30&#160;days of the MIBI imaging studies. Renal biopsy specimens were fixed in Dubosque-Brazil solution (150&#160;mL of 80% ethanol, 60&#160;mL of 40% formalin, 1&#160;g of picric acid, and 15&#160;mL of glacial acetic acid), post-fixed in 10% formaldehyde, and embedded in paraffin. Antibodies (anti-TOMM20; Santa Cruz Biotechnology; sc-17764) were applied to the paraffin-embedded sections of each specimen to assess mitochondrial content. The mitochondrial stain was scored based on the percentage of positive tubules (1, 0&#8211;9%; 2, 10&#8211;29%; 3,&#8201;&gt;&#8201;30%) and the intensity of staining (1, weak; 2, moderate; 3, strong). Finally, TOMM20 expression was classified into three grades based on the sum of the percentage and intensity scores: G1 (1&#8211;2), G2 (3&#8211;4), and G3 (5&#8211;6).</p></sec><sec id="Sec9"><title>Statistical analyses</title><p id="Par35">Clinical and imaging parameters were compared between the CKD and HV groups using a two-sample t-test or the Mann&#8211;Whitney U-test for continuous variables, and the Chi-squared test or Fisher&#8217;s exact test for categorical variables. Normality was assessed using the Shapiro&#8211;Wilk test. One-sided Pearson correlation tests were used to investigate correlations between MIBI parameters and conventional renal biomarkers. Spearman rank correlation was performed to investigate the correlation between renal mitochondrial content and conventional biomarkers and MIBI parameters. Univariable and multivariable logistic regression analyses were performed to identify independent predictors of CKD. The diagnostic performance of the SUV<sub>mean</sub> was evaluated by the area under the curve (AUC) in receiver operating characteristic (ROC) analysis. Statistical analyses were performed using MedCalc&#174; Statistical Software version 19.5.2 (MedCalc Software Ltd., Ostend, Belgium), with <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 considered indicative of statistical significance.</p></sec></sec><sec id="Sec10"><title>Results</title><sec id="Sec11"><title>Clinical characteristics</title><p id="Par36">In this study of 11 newly diagnosed CKD patients and 27 HVs, subjects had a median age of 31&#160;years, and 50% of subjects were female (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). In the CKD group, diagnoses included IgA nephropathy (n&#8201;=&#8201;5), Alport syndrome (n&#8201;=&#8201;1), and one case each of ischemic nephropathy, focal segmental glomerulosclerosis, steroid dependent minimal change disease, glomerular minor lesion, and lupus nephritis. BMI did not differ between the&#160;CKD and HV groups. In the CKD group, 54.5% of subjects demonstrated impaired eGFR<sub>SCr</sub> (&lt;&#8201;90&#160;mL/min/1.73 m<sup>2</sup>) and albuminuria (urine albumin/creatinine ratio&#8201;&gt;&#8201;30 &#956;g/mg) was present in 72.7%. Furthermore, urine microalbumin/creatinine ratio was elevated in the CKD group when compared to the HV group (115.9 &#956;g/mg vs. 5.1 &#956;g/mg, <italic toggle="yes">P</italic>&#8201;=&#8201;0.002).<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>Clinical characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">CKD (n&#8201;=&#8201;11)</th><th align="left" colspan="1" rowspan="1">HV (n&#8201;=&#8201;27)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age (y)</td><td align="left" colspan="1" rowspan="1">33 (21, 54.5)</td><td align="left" colspan="1" rowspan="1">31 (27.5, 37)</td><td char="." align="char" colspan="1" rowspan="1">0.847</td></tr><tr><td align="left" colspan="1" rowspan="1">Gender, female</td><td align="left" colspan="1" rowspan="1">6 (54.6%)</td><td align="left" colspan="1" rowspan="1">13 (48.1%)</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&gt;&#8201;0.999</td></tr><tr><td align="left" colspan="1" rowspan="1">Body mass index (kg/m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">23.1&#8201;&#177;&#8201;5.2</td><td align="left" colspan="1" rowspan="1">23.8&#8201;&#177;&#8201;3.5</td><td char="." align="char" colspan="1" rowspan="1">0.681</td></tr><tr><td align="left" colspan="1" rowspan="1">eGFR<sub>SCr</sub> (mL/min/1.73m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">95.4&#8201;&#177;&#8201;31.2</td><td align="left" colspan="1" rowspan="1">109.8&#8201;&#177;&#8201;10.2</td><td char="." align="char" colspan="1" rowspan="1">0.164</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Stage 1 (&#8805;&#8201;90)</td><td align="left" colspan="1" rowspan="1">5 (45.5%)</td><td align="left" colspan="1" rowspan="1">27 (100%)</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Stage 2 (60&#8211;89)</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">0</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Stage 3 (30&#8211;59)</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">0</td><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Urine albumin/creatinine ratio (&#956;g/mg)</td><td align="left" colspan="1" rowspan="1">115.9 (40.0, 473.2)</td><td align="left" colspan="1" rowspan="1">5.1 (4.0, 6.7)</td><td char="." align="char" colspan="1" rowspan="1">0.002</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&gt;&#8201;30</td><td align="left" colspan="1" rowspan="1">8 (72.7%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr></tbody></table><table-wrap-foot><p>Values in parentheses represent percentages for categorical variables and interquartile ranges for continuous variables</p><p>CKD, Chronic kidney disease; HV, Healthy volunteer; eGFR<sub>SCr</sub>, Serum creatinine-based eGFR</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec12"><title>Comparisons of DTPA renal scans between CKD and HV groups</title><p id="Par37">In the DTPA dynamic renal scans, the TAC reached a peak (T<sub>max</sub>) later in the CKD group than in the HV group (4.3 vs. 3.0&#160;min, <italic toggle="yes">P</italic>&#8201;=&#8201;0.008) (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). Moreover, delayed renal excretion (T<sub>1/2</sub>&#8201;&gt;&#8201;20&#160;min) was observed only in the CKD group (27.3%, <italic toggle="yes">P</italic>&#8201;=&#8201;0.020). However, DTPA %ID<sub>2&#8211;3&#160;min</sub> and GFR<sub>DTPA</sub> was not significantly different between the groups.<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>Results of DTPA and MIBI renal scans of the left kidneys</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">CKD (n&#8201;=&#8201;11)</th><th align="left" colspan="1" rowspan="1">HV (n&#8201;=&#8201;27)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="4" rowspan="1">DTPA dynamic scan</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;T<sub>max</sub> (min)</td><td align="left" colspan="1" rowspan="1">4.3 (3.1, 5.5)</td><td align="left" colspan="1" rowspan="1">3.0 (2.8, 3.3)</td><td char="." align="char" colspan="1" rowspan="1">0.008</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;T<sub>1/2</sub>&#8201;&gt;&#8201;20&#160;min</td><td align="left" colspan="1" rowspan="1">3 (27.3%)</td><td align="left" colspan="1" rowspan="1">0 (0%)</td><td char="." align="char" colspan="1" rowspan="1">0.020</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;%ID<sub>2&#8211;3&#160;min</sub></td><td align="left" colspan="1" rowspan="1">4.2&#8201;&#177;&#8201;1.4%</td><td align="left" colspan="1" rowspan="1">4.8&#8201;&#177;&#8201;0.8%</td><td char="." align="char" colspan="1" rowspan="1">0.192</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;GFR<sub>DTPA</sub> (mL/min)</td><td align="left" colspan="1" rowspan="1">37.8&#8201;&#177;&#8201;13.5</td><td align="left" colspan="1" rowspan="1">43.6&#8201;&#177;&#8201;7.9</td><td char="." align="char" colspan="1" rowspan="1">0.206</td></tr><tr><td align="left" colspan="4" rowspan="1">MIBI dynamic scan</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;T<sub>max</sub> (min)</td><td align="left" colspan="1" rowspan="1">3.1&#8201;&#177;&#8201;0.8</td><td align="left" colspan="1" rowspan="1">3.0&#8201;&#177;&#8201;0.6</td><td char="." align="char" colspan="1" rowspan="1">0.885</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;T<sub>1/2</sub>&#8201;&gt;&#8201;20&#160;min</td><td align="left" colspan="1" rowspan="1">4 (36.4%)</td><td align="left" colspan="1" rowspan="1">10 (37.0%)</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&gt;&#8201;0.999</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;%ID<sub>2&#8211;3&#160;min</sub></td><td align="left" colspan="1" rowspan="1">6.7&#8201;&#177;&#8201;2.4%</td><td align="left" colspan="1" rowspan="1">8.6&#8201;&#177;&#8201;1.4%</td><td char="." align="char" colspan="1" rowspan="1">0.027</td></tr><tr><td align="left" colspan="4" rowspan="1">MIBI SPECT/CT</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;SUV<sub>max</sub></td><td align="left" colspan="1" rowspan="1">12.4 (11.1, 12.9)</td><td align="left" colspan="1" rowspan="1">15.2 (13.9, 18.6)</td><td char="." align="char" colspan="1" rowspan="1">0.005</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;SUV<sub>mean</sub></td><td align="left" colspan="1" rowspan="1">6.3&#8201;&#177;&#8201;1.2</td><td align="left" colspan="1" rowspan="1">8.7&#8201;&#177;&#8201;1.7</td><td char="." align="char" colspan="1" rowspan="1">&#8201;&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Volume</td><td align="left" colspan="1" rowspan="1">182.1&#8201;&#177;&#8201;43.2</td><td align="left" colspan="1" rowspan="1">173.7&#8201;&#177;&#8201;37.9</td><td char="." align="char" colspan="1" rowspan="1">0.584</td></tr></tbody></table><table-wrap-foot><p>Values in parentheses represent percentages for categorical variables and interquartile ranges for continuous variables</p><p>CKD, Chronic kidney disease; HV, Healthy volunteer; T<sub>max</sub>, Time of maximum counts; T<sub>1/2</sub>, Time of half of maximum counts; %ID<sub>2&#8211;3&#160;min</sub>, Percentage of renal uptake relative to the injected radioactivity dose calculated from images acquired between 2 and 3&#160;min; GFR<sub>DTPA</sub>, Glomerular filtration rate calculated on DTPA scan; SUV<sub>max</sub>, Maximum standardized uptake value; SUV<sub>mean</sub>, Mean standardized uptake value</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec13"><title>Comparisons of MIBI renal scans between CKD and HV groups</title><p id="Par38">In the MIBI dynamic renal scans of HVs, renal uptake was clearly visualized and TAC analysis revealed a T<sub>max</sub> of 3.0&#8201;&#177;&#8201;0.6&#160;min, followed by rapid urinary excretion (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Subsequently, renal radioactivity reached a plateau, with residual&#160;MIBI retention in the kidney. Comparing the CKD and HV groups, renal MIBI uptake in the CKD group appeared less distinct, with poorly defined kidney contours. MIBI %ID<sub>2&#8211;3&#160;min</sub> was lower in the CKD group compared to the HV group (6.7&#8201;&#177;&#8201;2.4% vs. 8.6&#8201;&#177;&#8201;1.4%, <italic toggle="yes">P</italic>&#8201;=&#8201;0.027). However, the TAC pattern, including T<sub>max</sub> and renal excretion was not significantly different between the groups (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>).<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Representative MIBI images of a 26-year-old female healthy volunteer with an eGFR<sub>SCr</sub> of 103.6&#160;mL/min, urine albumin/creatinine ratio of 5.4 &#956;g/mg, and GFR<sub>DTPA</sub> of 42.7&#160;mL/min. <bold>a</bold> MIBI dynamic renal scan and <bold>b</bold> time activity curve showing a peak radioactivity in the left kidney at 3.0&#160;min, followed by rapid renal excretion (T<sub>1/2</sub> at 16.7&#160;min), after which radioactivity plateaued, with a slow elimination phase. The MIBI %ID<sub>2&#8211;3&#160;min</sub> of the left kidney was 9.6%. <bold>c</bold> Fusion coronal SPECT/CT showing well-demarcated homogeneous renal MIBI uptake; the SUV<sub>max</sub> and SUV<sub>mean</sub> of the left kidney were 16.7 and 10.0, respectively</p></caption><graphic id="MO1" position="float" orientation="portrait" xlink:href="13550_2025_1306_Fig1_HTML.jpg"/></fig></p><p id="Par39">In the MIBI SPECT/CT, HVs demonstrated high renal MIBI uptake, which was significantly higher than liver uptake. In contrast, CKD patients displayed less distinct MIBI uptake, with only mildly elevated uptake compared to the liver. Quantitative analysis revealed that both the kidney SUV<sub>max</sub> and SUV<sub>mean</sub> were lower in the CKD group than in the HV group (12.4 vs. 15.2, <italic toggle="yes">P</italic>&#8201;=&#8201;0.005 and 6.3&#8201;&#177;&#8201;1.2 vs. 8.7&#8201;&#177;&#8201;1.7, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, respectively) (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). Meanwhile, kidney volume was not significantly different between these groups.<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Representative MIBI images of a 22-year-old female patient newly diagnosed with IgA nephropathy with an eGFR<sub>SCr</sub> of 136.9&#160;mL/min, urine albumin/creatinine ratio of 96.2 &#956;g/mg, and GFR<sub>DTPA</sub> of 49.5&#160;mL/min. <bold>a</bold> MIBI dynamic renal scan and <bold>b</bold> time activity curve of the left kidney showed a T<sub>max</sub> at 2.3&#160;min and a T<sub>1/2</sub> at 13.2&#160;min. The MIBI %ID<sub>2&#8211;3&#160;min</sub> of the left kidney was 7.9%. <bold>c</bold> Fusion coronal SPECT/CT showed relatively fuzzy renal MIBI uptake compared to that of the healthy volunteers; the SUV<sub>max</sub> and SUV<sub>mean</sub> of the left kidney were 9.7 and 6.9, respectively</p></caption><graphic id="MO2" position="float" orientation="portrait" xlink:href="13550_2025_1306_Fig2_HTML.jpg"/></fig></p><p id="Par40">The liver, as the reference organ, showed no significant difference in MIBI uptake (i.e., SUV<sub>mean</sub>) between the CKD and HV groups (5.0&#8201;&#177;&#8201;1.5 vs. 4.4&#8201;&#177;&#8201;1.6, <italic toggle="yes">P</italic>&#8201;=&#8201;0.315).</p></sec><sec id="Sec14"><title>Correlations with conventional renal biomarkers</title><p id="Par41">MIBI %ID<sub>2&#8211;3&#160;min</sub> and SUV<sub>mean</sub> were positively correlated with eGFR<sub>SCr</sub>, DTPA %ID<sub>2&#8211;3&#160;min</sub>, and GFR<sub>DTPA</sub> (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). The SUV<sub>max</sub> displayed a week correlation with GFR<sub>DTPA</sub>. The SUV<sub>mean</sub> was the only parameter that was inversely correlated with urine albumin/creatinine ratio.<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table&#160;3</label><caption><p>Correlations between quantitative MIBI parameters and conventional renal biomarkers</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">MIBI %ID<sub>2&#8211;3&#160;min</sub></th><th align="left" colspan="1" rowspan="1">SUV<sub>max</sub></th><th align="left" colspan="1" rowspan="1">SUV<sub>mean</sub></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">eGFR<sub>SCr</sub></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">r</italic>&#8201;=&#8201;0.682***</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">r</italic>&#8201;=&#8201;0.251</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">r</italic>&#8201;=&#8201;0.418**</td></tr><tr><td align="left" colspan="1" rowspan="1">Urine albumin/creatinine ratio</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">r</italic>&#8201;=&#8201;&#8201;&#8722;&#8201;0.159</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">r</italic>&#8201;=&#8201;&#8201;&#8722;&#8201;0.249</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">r</italic>&#8201;=&#8201;&#8201;&#8722;&#8201;0.477**</td></tr><tr><td align="left" colspan="1" rowspan="1">DTPA %ID<sub>2&#8211;3&#160;min</sub></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">r</italic>&#8201;=&#8201;0.827***</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">r</italic>&#8201;=&#8201;0.276</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">r</italic>&#8201;=&#8201;0.490**</td></tr><tr><td align="left" colspan="1" rowspan="1">GFR<sub>DTPA</sub></td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">r</italic>&#8201;=&#8201;0.826***</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">r</italic>&#8201;=&#8201;0.275*</td><td align="left" colspan="1" rowspan="1"><italic toggle="yes">r</italic>&#8201;=&#8201;0.489***</td></tr></tbody></table><table-wrap-foot><p>%ID<sub>2&#8211;3&#160;min</sub>, Percentage of renal uptake relative to the injected radioactivity dose calculated from images acquired between 2 and 3&#160;min; SUV<sub>max</sub>, Maximum standardized uptake value; SUV<sub>mean</sub>, Mean standardized uptake value; eGFR<sub>SCr</sub>, Serum creatinine-based eGFR; GFR<sub>DTPA</sub>, Glomerular filtration rate calculated on DTPA scan</p><p>*<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05; **<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.01; ***<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec15"><title>Correlation between renal mitochondrial content and SUV<sub>mean</sub></title><p id="Par42">To assess the renal mitochondrial content of available kidney sections from 10 of the newly diagnosed CKD patients, excluding one patient who did not undergo kidney biopsy, immunohistochemical analysis of tubular TOMM20 expression was performed and assigned one of three grades (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>); G1 (n&#8201;=&#8201;3), G2 (n&#8201;=&#8201;3), and G3 (n&#8201;=&#8201;4). Among these groups, SUV<sub>mean</sub> showed a trend of increasing values (G1, SUVmean&#8201;=&#8201;5.04&#8201;&#177;&#8201;0.7; G2, SUV<sub>mean</sub>&#8201;=&#8201;6.65&#8201;&#177;&#8201;0.91; G3, SUV<sub>mean</sub>&#8201;=&#8201;7.04&#8201;&#177;&#8201;1.07; <italic toggle="yes">P</italic>&#8201;=&#8201;0.063). In addition, SUV<sub>mean</sub> was the only parameter that was positively correlated with renal mitochondrial content (Spearman's rho&#8201;=&#8201;0.636, <italic toggle="yes">P</italic>&#8201;=&#8201;0.024, Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). However, there was no relationship between renal mitochondrial content and eGFR<sub>SCr</sub>, urine albumin/creatinine ratio, DTPA %ID<sub>2&#8211;3&#160;min</sub>, GFR<sub>DTPA</sub> or other MIBI parameters (MIBI %ID<sub>2&#8211;3&#160;min</sub> and SUV<sub>max</sub>).<fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>Comparison of MIBI SPECT/CT images between the grades of IHC analysis of TOM20 expressionin proximal tubules from microscopy images (&#215;&#8201;200) (<bold>a</bold> G1; <bold>b</bold> G2; <bold>c</bold> G3)</p></caption><graphic id="MO3" position="float" orientation="portrait" xlink:href="13550_2025_1306_Fig3_HTML.jpg"/></fig><fig id="Fig4" position="float" orientation="portrait"><label>Fig.&#160;4</label><caption><p>Box plot (<bold>a</bold>) and scatter plot (<bold>b</bold>) with fitted line (Spearman's rho&#8201;=&#8201;0.636, <italic toggle="yes">P</italic>&#8201;=&#8201;0.024) of SUV<sub>mean</sub> of the kidney according to IHC grading</p></caption><graphic id="MO4" position="float" orientation="portrait" xlink:href="13550_2025_1306_Fig4_HTML.jpg"/></fig></p></sec><sec id="Sec16"><title>Diagnostic accuracy of SUV<sub>mean</sub></title><p id="Par43">Results of the univariable and multivariable logistic regression analyses are summarized in Table&#160;<xref rid="Tab4" ref-type="table">4</xref>. In the univariable analysis, T<sub>max</sub> and delayed excretion with T<sub>1/2</sub>&#8201;&gt;&#8201;20&#160;min on DTPA dynamic renal scan and MIBI %ID<sub>2&#8211;3&#160;min</sub>, SUV<sub>max</sub>, and SUV<sub>mean</sub> on MIBI imaging were identified as significant predictors of CKD. Among them, only SUV<sub>mean</sub> was found to be an independent predictor of CKD, with an adjusted odds ratio of 0.2 (95% confidence interval 0.0&#8211;0.9, <italic toggle="yes">P</italic>&#8201;=&#8201;0.037). In the ROC analyses, SUV<sub>mean</sub> was found to have a good diagnostic accuracy in identifying CKD, with an AUC of 0.886 (95% confidence interval 0.740&#8212;0.966, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>).<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table&#160;4</label><caption><p>Logistic regression analyses of conventional and MIBI parameters as predictors of CKD</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="2" rowspan="1">Univariable</th><th align="left" colspan="2" rowspan="1">Multivariable</th></tr><tr><th align="left" colspan="1" rowspan="1">Odds ratio</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic></th><th align="left" colspan="1" rowspan="1">Odds ratio</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic></th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">eGFR<sub>SCr</sub></td><td align="left" colspan="1" rowspan="1">1.0 (0.9&#8211;1.0)</td><td char="." align="char" colspan="1" rowspan="1">0.066</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Urine albumin/creatinine ratio</td><td align="left" colspan="1" rowspan="1">1.2 (0.8&#8211;1.7)</td><td char="." align="char" colspan="1" rowspan="1">0.445</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">DTPA T<sub>max</sub></td><td align="left" colspan="1" rowspan="1">2.1 (1.1&#8211;4.1)</td><td char="." align="char" colspan="1" rowspan="1">0.020</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">DTPA T<sub>1/2</sub>&#8201;&gt;&#8201;20&#160;min</td><td align="left" colspan="1" rowspan="1">1.8E+009</td><td char="." align="char" colspan="1" rowspan="1">0.003</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">MIBI %ID<sub>2&#8211;3&#160;min</sub></td><td align="left" colspan="1" rowspan="1">0.6 (0.4&#8211;0.8)</td><td char="." align="char" colspan="1" rowspan="1">0.012</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">MIBI SUV<sub>max</sub></td><td align="left" colspan="1" rowspan="1">0.7 (0.5&#8211;1.0)</td><td char="." align="char" colspan="1" rowspan="1">0.023</td><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">MIBI SUV<sub>mean</sub></td><td align="left" colspan="1" rowspan="1">0.3 (0.1&#8211;0.7)</td><td char="." align="char" colspan="1" rowspan="1">0.004</td><td align="left" colspan="1" rowspan="1">0.2 (0.0&#8211;0.9)</td><td char="." align="char" colspan="1" rowspan="1">0.037</td></tr></tbody></table><table-wrap-foot><p>Values in parentheses represent 95% confidence interval</p><p>CKD, Chronic kidney disease; eGFR<sub>SCr</sub>, Serum creatinine-based eGFR; T<sub>max</sub>, Time of maximum counts; T<sub>1/2</sub>, Time of half of maximum counts; %ID<sub>2&#8211;3&#160;min</sub>, Percentage of renal uptake relative to the injected radioactivity dose calculated from images acquired between 2 and 3&#160;min; SUV<sub>max</sub>, Maximum standardized uptake value; SUV<sub>mean</sub>, Mean standardized uptake value</p></table-wrap-foot></table-wrap><fig id="Fig5" position="float" orientation="portrait"><label>Fig.&#160;5</label><caption><p>ROC curve of SUV<sub>mean</sub> of the kidney (AUC 0.886) for diagnosing CKD</p></caption><graphic id="MO5" position="float" orientation="portrait" xlink:href="13550_2025_1306_Fig5_HTML.jpg"/></fig></p></sec></sec><sec id="Sec17"><title>Discussion</title><p id="Par44">This study demonstrates the potential of repurposing MIBI SPECT/CT technology to visualize subcellular mitochondrial activity in the kidneys of CKD patients. MIBI is an established radiotracer extensively investigated for myocardial perfusion imaging based on its mitochondrial retention. Given the growing role of renal mitochondrial dysfunction in the pathophysiology of various kidney diseases, we repurposed MIBI to evaluate renal mitochondrial function, extending from its conventional role in myocardial viability assessment. Renal mitochondrial function was assessed via MIBI imaging, and SPECT/CT revealed a significant reduction in renal MIBI uptake in CKD patients compared to HVs, with SUV<sub>mean</sub> positively correlating with renal mitochondrial content assessed by immunohistochemical analysis of renal biopsy specimens. However, no relationships were found between renal mitochondrial content and conventional biomarkers, such as eGFR<sub>SCr</sub>, urine albumin/creatinine ratio, and DTPA scan parameters. Given that these biomarkers are not sensitive for early renal dysfunction [<xref ref-type="bibr" rid="CR31">31</xref>], our findings underscore the potential advantages of MIBI imaging as a non-invasive approach to visualize renal mitochondrial dysfunction.</p><p id="Par45">Recent preclinical studies by Saeki et al. have explored the use of novel PET tracer, <sup>18</sup>F-BCPP-BF, to non-invasively assess renal mitochondrial dysfunction [<xref ref-type="bibr" rid="CR8">8</xref>]. <sup>18</sup>F-BCPP-BF targets mitochondrial complex I and demonstrated good correlation with mitochondrial integrity and renal functional decline across various rodent models of kidney disease. <sup>18</sup>F-BCPP-BF PET detected mitochondrial abnormalities even before overt functional deterioration, suggesting potential for early detection of kidney injury. In the present study, enrolled patients were mostly in the earlier stages of CKD, with 45.5% in stage 1 and another 45.5% in stage 2. Notably, kidney volume measured on the CT component of SPECT/CT did not significantly differ between CKD patients and HVs, likely because structural changes become apparent in the later stages of disease. Despite normal or minimally impaired eGFR in the CKD patients, renal mitochondrial dysfunction was detected by MIBI SPECT/CT, supporting its potential utility for early detection of kidney pathology. This ability to visualize mitochondrial dysfunction at early disease stages is clinically valuable, as early detection and intervention are critical for improving CKD outcomes. While translation of <sup>18</sup>F-BCPP-BF PET into clinical practice may be limited by regulatory requirements, MIBI SPECT/CT offers a readily available imaging modality with immediate applicability for the evaluation of renal mitochondrial dysfunction in CKD patients.</p><p id="Par46">MIBI planar imaging has previously been shown to detect early renal mitochondrial dysfunction following ischemia&#8211;reperfusion injury in a preclinical porcine model [<xref ref-type="bibr" rid="CR32">32</xref>]. Reduced MIBI uptake in kidneys likely reflects diminished mitochondrial membrane potential and structural integrity, indicating compromised mitochondrial function. Our study advances the methodology by applying quantitative SPECT/CT, which enables three-dimensional assessment, improved spatial resolution, and precise quantitation of radiotracer accumulation. Furthermore, by validating renal MIBI uptake against mitochondrial content in human biopsy specimens and evaluating patients with CKD, our study highlights the broader clinical utility and translational potential of mitochondrial imaging. Mitochondrial dysfunction plays a significant role not only in the initial injury but also in CKD progression, contributing to various pathological processes that exacerbate renal damage and functional decline as the disease advances [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Understanding this relationship is crucial for developing targeted therapies and improving outcomes for CKD patients. Future studies on MIBI imaging should investigate its clinical implications for risk stratification and the assessment of mitochondria-targeted therapeutic intervention in CKD management.</p><p id="Par47">The MIBI imaging consisted of two phases: the first is a dynamic renal scan, considered early imaging, while the second is SPECT/CT, regarded as delayed imaging. In the dynamic scan started immediately after radiotracer injection, MIBI %ID<sub>2&#8211;3&#160;min</sub> showed a strong positive correlation with eGFR<sub>SCr</sub>, DTPA %ID<sub>2&#8211;3&#160;min</sub>, and GFR<sub>DTPA</sub>. This suggests that the early imaging primarily reflects renal blood flow. In the SPECT/CT obtained 35&#160;min post-injection, SUV<sub>mean</sub> was inversely correlated with urine albumin/creatinine ratio, indicating that delayed imaging may be more suitable for assessing kidney damage related to mitochondrial dysfunction. This finding aligns with a previous study showing that MIBI retained in tissues after early elimination is bound to mitochondria [<xref ref-type="bibr" rid="CR35">35</xref>]. For SPECT/CT, SUV<sub>mean</sub> demonstrated greater reliability than SUV<sub>max</sub> in correlating renal mitochondrial dysfunction and predicting CKD. This aligns with previous studies which suggest that SUV<sub>mean</sub>, by incorporating the entire kidney VOI, provides a more stable measure of organ-wide mitochondrial function [<xref ref-type="bibr" rid="CR36">36</xref>]. Additionally, the diagnostic accuracy of SUV<sub>mean</sub> (AUC&#8201;=&#8201;0.886) supports its potential to surpass traditional biomarkers, which often miss early mitochondrial and cellular changes.</p><p id="Par48">Despite the promising findings, this study had several limitations. It was a small, single-center study with no longitudinal follow-up data. Therefore, the influence of MIBI imaging on the current management and its prognostic value could not be addressed. Technical considerations also remain. Although MIBI uptake depends primarily on mitochondrial function, MIBI is also a substrate for multidrug resistance (MDR) proteins, such as P-glycoprotein (P-GP). MIBI washout may increase with P-GP expression in renal tubular cells, reflecting decreased renal MIBI uptake over time [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. However, P-GP expression was not evaluated in this study, which may influence MIBI pharmacokinetics. To mitigate this effect, renal SPECT/CT was performed approximately 35&#160;min after MIBI injection, when initial excretion had plateaued, targeting an earlier phase less affected by delayed washout. Moreover, the right kidney was excluded from analysis due to possible interference from bowel activity, as MIBI is excreted through both the urinary and hepatobiliary systems. Future studies should address these limitations by optimizing imaging timing and evaluating P-GP expression.</p></sec><sec id="Sec18"><title>Conclusions</title><p id="Par49">MIBI SPECT/CT offers a promising non-invasive approach to visualize renal mitochondrial dysfunction with SUV<sub>mean</sub> demonstrating a significant correlation with renal mitochondrial content. MIBI SPECT/CT could have utility as an imaging biomarker for the early detection of CKD, earlier than conventional biomarkers can detect. The technological repurposing of MIBI allows us to move beyond perfusion imaging toward mitochondrial imaging, potentially transforming nuclear nephrology and preventive care strategies. Further prospective multi-center studies with larger sample sizes and longitudinal follow-up are warranted to validate its diagnostic value, explore clinical applications, and assess its&#160;prognostic implications in CKD.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AUC</term><def><p id="Par4">Area under the curve</p></def></def-item><def-item><term>CKD</term><def><p id="Par5">Chronic kidney disease</p></def></def-item><def-item><term>DTPA</term><def><p id="Par6">[<sup>99M</sup>Tc]TcDTPA<sup>2&#8722;</sup></p></def></def-item><def-item><term>eGFR<sub>SCr</sub></term><def><p id="Par7">Serum creatinine-based estimated glomerular filtration rate</p></def></def-item><def-item><term>GFR</term><def><p id="Par8">Glomerular filtration rate</p></def></def-item><def-item><term>GFR<sub>DTPA</sub></term><def><p id="Par9">Glomerular filtration rate calculated on [<sup>99m</sup>Tc]TcDTPA<sup>2&#8722;</sup> scan</p></def></def-item><def-item><term>HV</term><def><p id="Par10">Healthy volunteers</p></def></def-item><def-item><term>MIBI</term><def><p id="Par11">[<sup>99M</sup>Tc]Tc-MIBI</p></def></def-item><def-item><term>NM</term><def><p id="Par12">Nuclear medicine</p></def></def-item><def-item><term>ROC</term><def><p id="Par13">Receiver operating characteristic</p></def></def-item><def-item><term>ROI</term><def><p id="Par14">Region of interest</p></def></def-item><def-item><term>SPECT/CT</term><def><p id="Par15">Single photon emission computed tomography and computed tomography</p></def></def-item><def-item><term>SUV</term><def><p id="Par16">Standardized uptake value</p></def></def-item><def-item><term>SUV<sub>max</sub></term><def><p id="Par17">Maximum standardized uptake value</p></def></def-item><def-item><term>SUV<sub>mean</sub></term><def><p id="Par18">Mean standardized uptake value</p></def></def-item><def-item><term>TAC</term><def><p id="Par19">Time activity curve</p></def></def-item><def-item><term>T<sub>max</sub></term><def><p id="Par20">Time of maximum counts</p></def></def-item><def-item><term>T<sub>1/2</sub></term><def><p id="Par21">Time of half of maximum counts</p></def></def-item><def-item><term>VOI</term><def><p id="Par22">Volume of interest</p></def></def-item><def-item><term>%ID<sub>2&#8211;3</sub><sub>&#160;min</sub></term><def><p id="Par23">The percentage of renal uptake relative to the injected radioactivity dose calculated from images acquired between 2 and 3&#160;min</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>All authors contributed to the study conception and design. SBP, CHL, SJ, HK, JSJ, and SHK were involved in data acquisition, collection, and analysis. SBP and SHK wrote the manuscript. All authors reviewed and approved the final version.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by the National Research Foundation of Korea (NRF) Grant funded by the Korea government (MSIP) (No. NRF-2020R1G1A1102033, NRF-2022R1A2C1007571, RS-2023-00219563), and the Soonchunhyang University Research Fund.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par50">This study was conducted in accordance with the ethical standards of the institutional and/or national research committee and the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Approval was granted by the Institutional Review Board of Soonchunhyang University Seoul Hospital (No. 2020&#8211;07-017). Written informed consent was obtained from all participants included in the study.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par51">Written informed consent was obtained from all participants included in the study.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par52">The authors declare that they have no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levey</surname><given-names>AS</given-names></name><name name-style="western"><surname>Eckardt</surname><given-names>KU</given-names></name><name name-style="western"><surname>Tsukamoto</surname><given-names>Y</given-names></name><name name-style="western"><surname>Levin</surname><given-names>A</given-names></name><name name-style="western"><surname>Coresh</surname><given-names>J</given-names></name><name name-style="western"><surname>Rossert</surname><given-names>J</given-names></name><etal/></person-group><article-title>Definition and classification of chronic kidney disease: a position statement from Kidney Disease: improving global outcomes (KDIGO)</article-title><source>Kidney Int</source><year>2005</year><volume>67</volume><fpage>2089</fpage><lpage>2100</lpage><pub-id pub-id-type="doi">10.1111/j.1523-1755.2005.00365.x</pub-id><pub-id pub-id-type="pmid">15882252</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: improving global outcomes (KDIGO). Kidney Int. 2005;67:2089&#8211;100. 10.1111/j.1523-1755.2005.00365.x.<pub-id pub-id-type="pmid">15882252</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1523-1755.2005.00365.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Francis</surname><given-names>A</given-names></name><name name-style="western"><surname>Harhay</surname><given-names>MN</given-names></name><name name-style="western"><surname>Ong</surname><given-names>ACM</given-names></name><name name-style="western"><surname>Tummalapalli</surname><given-names>SL</given-names></name><name name-style="western"><surname>Ortiz</surname><given-names>A</given-names></name><name name-style="western"><surname>Fogo</surname><given-names>AB</given-names></name><etal/></person-group><article-title>Chronic kidney disease and the global public health agenda: an international consensus</article-title><source>Nat Rev Nephrol</source><year>2024</year><pub-id pub-id-type="doi">10.1038/s41581-024-00820-6</pub-id><pub-id pub-id-type="pmid">38570631</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Francis A, Harhay MN, Ong ACM, Tummalapalli SL, Ortiz A, Fogo AB, et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol. 2024. 10.1038/s41581-024-00820-6.<pub-id pub-id-type="pmid">38570631</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41581-024-00820-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Botev</surname><given-names>R</given-names></name><name name-style="western"><surname>Malli&#233;</surname><given-names>JP</given-names></name><name name-style="western"><surname>Wetzels</surname><given-names>JFM</given-names></name><name name-style="western"><surname>Couchoud</surname><given-names>C</given-names></name><name name-style="western"><surname>Sch&#252;ck</surname><given-names>O</given-names></name></person-group><article-title>The clinician and estimation of glomerular filtration rate by creatinine-based formulas: current limitations and quo vadis</article-title><source>Clin J Am Soc Nephrol</source><year>2011</year><volume>6</volume><fpage>937</fpage><lpage>950</lpage><pub-id pub-id-type="doi">10.2215/CJN.09241010</pub-id><pub-id pub-id-type="pmid">21454722</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Botev R, Malli&#233; JP, Wetzels JFM, Couchoud C, Sch&#252;ck O. The clinician and estimation of glomerular filtration rate by creatinine-based formulas: current limitations and quo vadis. Clin J Am Soc Nephrol. 2011;6:937&#8211;50. 10.2215/CJN.09241010.<pub-id pub-id-type="pmid">21454722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2215/CJN.09241010</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prigent</surname><given-names>A</given-names></name></person-group><article-title>Monitoring renal function and limitations of renal function tests</article-title><source>Semin Nucl Med</source><year>2008</year><volume>38</volume><fpage>32</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1053/j.semnuclmed.2007.09.003</pub-id><pub-id pub-id-type="pmid">18096462</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Prigent A. Monitoring renal function and limitations of renal function tests. Semin Nucl Med. 2008;38:32&#8211;46. 10.1053/j.semnuclmed.2007.09.003.<pub-id pub-id-type="pmid">18096462</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.semnuclmed.2007.09.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alaini</surname><given-names>A</given-names></name><name name-style="western"><surname>Malhotra</surname><given-names>D</given-names></name><name name-style="western"><surname>Rondon-Berrios</surname><given-names>H</given-names></name><name name-style="western"><surname>Argyropoulos</surname><given-names>CP</given-names></name><name name-style="western"><surname>Khitan</surname><given-names>ZJ</given-names></name><name name-style="western"><surname>Raj</surname><given-names>DSC</given-names></name><etal/></person-group><article-title>Establishing the presence or absence of chronic kidney disease: uses and limitations of formulas estimating the glomerular filtration rate</article-title><source>World J Methodol</source><year>2017</year><volume>7</volume><issue>3</issue><fpage>73</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.5662/wjm.v7.i3.73</pub-id><pub-id pub-id-type="pmid">29026688</pub-id><pub-id pub-id-type="pmcid">PMC5618145</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Alaini A, Malhotra D, Rondon-Berrios H, Argyropoulos CP, Khitan ZJ, Raj DSC, et al. Establishing the presence or absence of chronic kidney disease: uses and limitations of formulas estimating the glomerular filtration rate. World J Methodol. 2017;7(3):73&#8211;92. 10.5662/wjm.v7.i3.73.<pub-id pub-id-type="pmid">29026688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5662/wjm.v7.i3.73</pub-id><pub-id pub-id-type="pmcid">PMC5618145</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bagshaw</surname><given-names>SM</given-names></name><name name-style="western"><surname>Gibney</surname><given-names>RTN</given-names></name></person-group><article-title>Conventional markers of kidney function</article-title><source>Crit Care Med</source><year>2008</year><volume>36</volume><fpage>S152</fpage><pub-id pub-id-type="doi">10.1097/CCM.0b013e318168c613</pub-id><pub-id pub-id-type="pmid">18382187</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Bagshaw SM, Gibney RTN. Conventional markers of kidney function. Crit Care Med. 2008;36:S152. 10.1097/CCM.0b013e318168c613.<pub-id pub-id-type="pmid">18382187</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CCM.0b013e318168c613</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stevens</surname><given-names>LA</given-names></name><name name-style="western"><surname>Levey</surname><given-names>AS</given-names></name></person-group><article-title>Current status and future perspectives for CKD testing</article-title><source>Am J Kidney Dis</source><year>2009</year><volume>53</volume><fpage>S17</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1053/j.ajkd.2008.07.047</pub-id><pub-id pub-id-type="pmid">19231757</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Stevens LA, Levey AS. Current status and future perspectives for CKD testing. Am J Kidney Dis. 2009;53:S17-26. 10.1053/j.ajkd.2008.07.047.<pub-id pub-id-type="pmid">19231757</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.ajkd.2008.07.047</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saeki</surname><given-names>S</given-names></name><name name-style="western"><surname>Ohba</surname><given-names>H</given-names></name><name name-style="western"><surname>Ube</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>K</given-names></name><name name-style="western"><surname>Haruyama</surname><given-names>W</given-names></name><name name-style="western"><surname>Uchii</surname><given-names>M</given-names></name><etal/></person-group><article-title>Positron emission tomography imaging of renal mitochondria is a powerful tool in the study of acute and progressive kidney disease models</article-title><source>Kidney Int</source><year>2020</year><volume>98</volume><fpage>88</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.kint.2020.02.024</pub-id><pub-id pub-id-type="pmid">32471638</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Saeki S, Ohba H, Ube Y, Tanaka K, Haruyama W, Uchii M, et al. Positron emission tomography imaging of renal mitochondria is a powerful tool in the study of acute and progressive kidney disease models. Kidney Int. 2020;98:88&#8211;99. 10.1016/j.kint.2020.02.024.<pub-id pub-id-type="pmid">32471638</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.kint.2020.02.024</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xue</surname><given-names>L</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Liang</surname><given-names>H</given-names></name></person-group><article-title>Urinary mitochondrial DNA may be useful in diagnosing early diabetic nephropathy</article-title><source>Exp Ther Med</source><year>2023</year><volume>26</volume><fpage>570</fpage><pub-id pub-id-type="doi">10.3892/etm.2023.12270</pub-id><pub-id pub-id-type="pmid">38023365</pub-id><pub-id pub-id-type="pmcid">PMC10652235</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Xue L, Yang X, Song Y, Wang C, Zhou J, Liang H. Urinary mitochondrial DNA may be useful in diagnosing early diabetic nephropathy. Exp Ther Med. 2023;26:570. 10.3892/etm.2023.12270.<pub-id pub-id-type="pmid">38023365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/etm.2023.12270</pub-id><pub-id pub-id-type="pmcid">PMC10652235</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhatia</surname><given-names>D</given-names></name><name name-style="western"><surname>Capili</surname><given-names>A</given-names></name><name name-style="western"><surname>Choi</surname><given-names>ME</given-names></name></person-group><article-title>Mitochondrial dysfunction in kidney injury, inflammation, and disease: potential therapeutic approaches</article-title><source>Kidney Res Clin Pract</source><year>2020</year><volume>39</volume><fpage>244</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.23876/j.krcp.20.082</pub-id><pub-id pub-id-type="pmid">32868492</pub-id><pub-id pub-id-type="pmcid">PMC7530368</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Bhatia D, Capili A, Choi ME. Mitochondrial dysfunction in kidney injury, inflammation, and disease: potential therapeutic approaches. Kidney Res Clin Pract. 2020;39:244&#8211;58. 10.23876/j.krcp.20.082.<pub-id pub-id-type="pmid">32868492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.23876/j.krcp.20.082</pub-id><pub-id pub-id-type="pmcid">PMC7530368</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srivastava</surname><given-names>A</given-names></name><name name-style="western"><surname>Tomar</surname><given-names>B</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>D</given-names></name><name name-style="western"><surname>Rath</surname><given-names>SK</given-names></name></person-group><article-title>Mitochondrial dysfunction and oxidative stress: role in chronic kidney disease</article-title><source>Life Sci</source><year>2023</year><volume>319</volume><fpage>121432</fpage><pub-id pub-id-type="doi">10.1016/j.lfs.2023.121432</pub-id><pub-id pub-id-type="pmid">36706833</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Srivastava A, Tomar B, Sharma D, Rath SK. Mitochondrial dysfunction and oxidative stress: role in chronic kidney disease. Life Sci. 2023;319:121432. 10.1016/j.lfs.2023.121432.<pub-id pub-id-type="pmid">36706833</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lfs.2023.121432</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galvan</surname><given-names>DL</given-names></name><name name-style="western"><surname>Green</surname><given-names>NH</given-names></name><name name-style="western"><surname>Danesh</surname><given-names>FR</given-names></name></person-group><article-title>The hallmarks of mitochondrial dysfunction in chronic kidney disease</article-title><source>Kidney Int</source><year>2017</year><volume>92</volume><fpage>1051</fpage><lpage>1057</lpage><pub-id pub-id-type="doi">10.1016/j.kint.2017.05.034</pub-id><pub-id pub-id-type="pmid">28893420</pub-id><pub-id pub-id-type="pmcid">PMC5667560</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Galvan DL, Green NH, Danesh FR. The hallmarks of mitochondrial dysfunction in chronic kidney disease. Kidney Int. 2017;92:1051&#8211;7. 10.1016/j.kint.2017.05.034.<pub-id pub-id-type="pmid">28893420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.kint.2017.05.034</pub-id><pub-id pub-id-type="pmcid">PMC5667560</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Granata</surname><given-names>S</given-names></name><name name-style="western"><surname>Dalla Gassa</surname><given-names>A</given-names></name><name name-style="western"><surname>Tomei</surname><given-names>P</given-names></name><name name-style="western"><surname>Lupo</surname><given-names>A</given-names></name><name name-style="western"><surname>Zaza</surname><given-names>G</given-names></name></person-group><article-title>Mitochondria: a new therapeutic target in chronic kidney disease</article-title><source>Nutr Metab (Lond)</source><year>2015</year><volume>12</volume><fpage>49</fpage><pub-id pub-id-type="doi">10.1186/s12986-015-0044-z</pub-id><pub-id pub-id-type="pmid">26612997</pub-id><pub-id pub-id-type="pmcid">PMC4660721</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Granata S, Dalla Gassa A, Tomei P, Lupo A, Zaza G. Mitochondria: a new therapeutic target in chronic kidney disease. Nutr Metab (Lond). 2015;12:49. 10.1186/s12986-015-0044-z.<pub-id pub-id-type="pmid">26612997</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12986-015-0044-z</pub-id><pub-id pub-id-type="pmcid">PMC4660721</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanriover</surname><given-names>C</given-names></name><name name-style="western"><surname>Copur</surname><given-names>S</given-names></name><name name-style="western"><surname>Ucku</surname><given-names>D</given-names></name><name name-style="western"><surname>Cakir</surname><given-names>AB</given-names></name><name name-style="western"><surname>Hasbal</surname><given-names>NB</given-names></name><name name-style="western"><surname>Soler</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Kanbay</surname><given-names>M</given-names></name></person-group><article-title>The mitochondrion: a promising target for kidney disease</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><fpage>570</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics15020570</pub-id><pub-id pub-id-type="pmid">36839892</pub-id><pub-id pub-id-type="pmcid">PMC9960839</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Tanriover C, Copur S, Ucku D, Cakir AB, Hasbal NB, Soler MJ, Kanbay M. The mitochondrion: a promising target for kidney disease. Pharmaceutics. 2023;15:570. 10.3390/pharmaceutics15020570.<pub-id pub-id-type="pmid">36839892</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics15020570</pub-id><pub-id pub-id-type="pmcid">PMC9960839</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuznetsov</surname><given-names>AV</given-names></name><name name-style="western"><surname>Javadov</surname><given-names>S</given-names></name><name name-style="western"><surname>Margreiter</surname><given-names>R</given-names></name><name name-style="western"><surname>Hagenbuchner</surname><given-names>J</given-names></name><name name-style="western"><surname>Ausserlechner</surname><given-names>MJ</given-names></name></person-group><article-title>Analysis of mitochondrial function, structure, and intracellular organization in situ in cardiomyocytes and skeletal muscles</article-title><source>Int J Mol Sci</source><year>2022</year><pub-id pub-id-type="doi">10.3390/ijms23042252</pub-id><pub-id pub-id-type="pmid">35216368</pub-id><pub-id pub-id-type="pmcid">PMC8876605</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Kuznetsov AV, Javadov S, Margreiter R, Hagenbuchner J, Ausserlechner MJ. Analysis of mitochondrial function, structure, and intracellular organization in situ in cardiomyocytes and skeletal muscles. Int J Mol Sci. 2022. 10.3390/ijms23042252.<pub-id pub-id-type="pmid">35216368</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23042252</pub-id><pub-id pub-id-type="pmcid">PMC8876605</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shen</surname><given-names>H</given-names></name></person-group><article-title>Common methods in mitochondrial research (review)</article-title><source>Int J Mol Med</source><year>2022</year><pub-id pub-id-type="doi">10.3892/ijmm.2022.5182</pub-id><pub-id pub-id-type="pmid">36004457</pub-id><pub-id pub-id-type="pmcid">PMC9448300</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Yin Y, Shen H. Common methods in mitochondrial research (review). Int J Mol Med. 2022. 10.3892/ijmm.2022.5182.<pub-id pub-id-type="pmid">36004457</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijmm.2022.5182</pub-id><pub-id pub-id-type="pmcid">PMC9448300</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brand</surname><given-names>MD</given-names></name><name name-style="western"><surname>Nicholls</surname><given-names>DG</given-names></name></person-group><article-title>Assessing mitochondrial dysfunction in cells</article-title><source>Biochem J</source><year>2011</year><volume>435</volume><fpage>297</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1042/bj20110162</pub-id><pub-id pub-id-type="pmid">21726199</pub-id><pub-id pub-id-type="pmcid">PMC3076726</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Brand MD, Nicholls DG. Assessing mitochondrial dysfunction in cells. Biochem J. 2011;435:297&#8211;312. 10.1042/bj20110162.<pub-id pub-id-type="pmid">21726199</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BJ20110162</pub-id><pub-id pub-id-type="pmcid">PMC3076726</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Werner</surname><given-names>RA</given-names></name><name name-style="western"><surname>Pomper</surname><given-names>MG</given-names></name><name name-style="western"><surname>Buck</surname><given-names>AK</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>SP</given-names></name><name name-style="western"><surname>Higuchi</surname><given-names>T</given-names></name></person-group><article-title>SPECT and PET radiotracers in renal imaging</article-title><source>Semin Nucl Med</source><year>2022</year><volume>52</volume><fpage>406</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1053/j.semnuclmed.2021.12.003</pub-id><pub-id pub-id-type="pmid">35058040</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Werner RA, Pomper MG, Buck AK, Rowe SP, Higuchi T. SPECT and PET radiotracers in renal imaging. Semin Nucl Med. 2022;52:406&#8211;18. 10.1053/j.semnuclmed.2021.12.003.<pub-id pub-id-type="pmid">35058040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.semnuclmed.2021.12.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Durand</surname><given-names>E</given-names></name><name name-style="western"><surname>Chaumet-Riffaud</surname><given-names>P</given-names></name><name name-style="western"><surname>Grenier</surname><given-names>N</given-names></name></person-group><article-title>Functional renal imaging: new trends in radiology and nuclear medicine</article-title><source>Semin Nucl Med</source><year>2011</year><volume>41</volume><fpage>61</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1053/j.semnuclmed.2010.08.003</pub-id><pub-id pub-id-type="pmid">21111860</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Durand E, Chaumet-Riffaud P, Grenier N. Functional renal imaging: new trends in radiology and nuclear medicine. Semin Nucl Med. 2011;41:61&#8211;72. 10.1053/j.semnuclmed.2010.08.003.<pub-id pub-id-type="pmid">21111860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.semnuclmed.2010.08.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reichkendler</surname><given-names>MH</given-names></name><name name-style="western"><surname>Berg</surname><given-names>RMG</given-names></name><name name-style="western"><surname>de Nijs</surname><given-names>R</given-names></name><name name-style="western"><surname>Norgaard</surname><given-names>H</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>IM</given-names></name><name name-style="western"><surname>Borgwardt</surname><given-names>L</given-names></name></person-group><article-title>Planar scan vs. SPECT/low-dose CT for estimating split renal function by (99m)Tc-DMSA scintigraphy in children</article-title><source>Eur J Nucl Med Mol Imaging.</source><year>2020</year><volume>47</volume><fpage>729</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1007/s00259-019-04575-2</pub-id><pub-id pub-id-type="pmid">31728589</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Reichkendler MH, Berg RMG, de Nijs R, Norgaard H, Schmidt IM, Borgwardt L. Planar scan vs. SPECT/low-dose CT for estimating split renal function by (99m)Tc-DMSA scintigraphy in children. Eur J Nucl Med Mol Imaging. 2020;47:729&#8211;33. 10.1007/s00259-019-04575-2.<pub-id pub-id-type="pmid">31728589</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00259-019-04575-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keramida</surname><given-names>G</given-names></name><name name-style="western"><surname>James</surname><given-names>JM</given-names></name><name name-style="western"><surname>Prescott</surname><given-names>MC</given-names></name><name name-style="western"><surname>Peters</surname><given-names>AM</given-names></name></person-group><article-title>Pitfalls and limitations of radionuclide renal imaging in adults</article-title><source>Semin Nucl Med</source><year>2015</year><volume>45</volume><fpage>428</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1053/j.semnuclmed.2015.02.008</pub-id><pub-id pub-id-type="pmid">26278854</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Keramida G, James JM, Prescott MC, Peters AM. Pitfalls and limitations of radionuclide renal imaging in adults. Semin Nucl Med. 2015;45:428&#8211;39. 10.1053/j.semnuclmed.2015.02.008.<pub-id pub-id-type="pmid">26278854</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.semnuclmed.2015.02.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>P</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J-M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X-M</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W-J</given-names></name><name name-style="western"><surname>Pan</surname><given-names>L-P</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H-Y</given-names></name></person-group><article-title>99mTc-DTPA renal dynamic imaging method may be unsuitable to be used as the reference method in investigating the validity of CDK-EPI equation for determining glomerular filtration rate</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><fpage>e62328</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0062328</pub-id><pub-id pub-id-type="pmid">23658724</pub-id><pub-id pub-id-type="pmcid">PMC3641057</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Xie P, Huang J-M, Liu X-M, Wu W-J, Pan L-P, Lin H-Y. 99mTc-DTPA renal dynamic imaging method may be unsuitable to be used as the reference method in investigating the validity of CDK-EPI equation for determining glomerular filtration rate. PLoS ONE. 2013;8:e62328. 10.1371/journal.pone.0062328.<pub-id pub-id-type="pmid">23658724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0062328</pub-id><pub-id pub-id-type="pmcid">PMC3641057</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crane</surname><given-names>P</given-names></name><name name-style="western"><surname>Lalibert&#233;</surname><given-names>R</given-names></name><name name-style="western"><surname>Heminway</surname><given-names>S</given-names></name><name name-style="western"><surname>Thoolen</surname><given-names>M</given-names></name><name name-style="western"><surname>Orlandi</surname><given-names>C</given-names></name></person-group><article-title>Effect of mitochondrial viability and metabolism on technetium-99m-sestamibi myocardial retention</article-title><source>Eur J Nucl Med</source><year>1993</year><volume>20</volume><fpage>20</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1007/BF02261241</pub-id><pub-id pub-id-type="pmid">7678396</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Crane P, Lalibert&#233; R, Heminway S, Thoolen M, Orlandi C. Effect of mitochondrial viability and metabolism on technetium-99m-sestamibi myocardial retention. Eur J Nucl Med. 1993;20:20&#8211;5. 10.1007/BF02261241.<pub-id pub-id-type="pmid">7678396</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BF02261241</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strauss</surname><given-names>HW</given-names></name></person-group><article-title>MIBI and mitochondria</article-title><source>J Am Coll Cardiol</source><year>2013</year><volume>61</volume><fpage>2018</fpage><lpage>2019</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2013.02.026</pub-id><pub-id pub-id-type="pmid">23501384</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Strauss HW. MIBI and mitochondria. J Am Coll Cardiol. 2013;61:2018&#8211;9. 10.1016/j.jacc.2013.02.026.<pub-id pub-id-type="pmid">23501384</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2013.02.026</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>JW</given-names></name><name name-style="western"><surname>Hong</surname><given-names>SP</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name><name name-style="western"><surname>Moon</surname><given-names>SH</given-names></name><name name-style="western"><surname>Cho</surname><given-names>YS</given-names></name><name name-style="western"><surname>Jung</surname><given-names>KH</given-names></name><etal/></person-group><article-title><sup>99m</sup>Tc-MIBI uptake as a marker of mitochondrial membrane potential in cancer cells and effects of MDR1 and verapamil</article-title><source>PLoS ONE</source><year>2020</year><volume>15</volume><fpage>e0228848</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0228848</pub-id><pub-id pub-id-type="pmid">32050000</pub-id><pub-id pub-id-type="pmcid">PMC7015412</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Park JW, Hong SP, Lee JH, Moon SH, Cho YS, Jung KH, et al. <sup>99m</sup>Tc-MIBI uptake as a marker of mitochondrial membrane potential in cancer cells and effects of MDR1 and verapamil. PLoS ONE. 2020;15:e0228848. 10.1371/journal.pone.0228848.<pub-id pub-id-type="pmid">32050000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0228848</pub-id><pub-id pub-id-type="pmcid">PMC7015412</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiu</surname><given-names>ML</given-names></name><name name-style="western"><surname>Kronauge</surname><given-names>JF</given-names></name><name name-style="western"><surname>Piwnica-Worms</surname><given-names>D</given-names></name></person-group><article-title>Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium(I) in cultured mouse fibroblasts</article-title><source>J Nucl Med</source><year>1990</year><volume>31</volume><fpage>1646</fpage><lpage>1653</lpage><pub-id pub-id-type="pmid">2213187</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium(I) in cultured mouse fibroblasts. J Nucl Med. 1990;31:1646&#8211;53.<pub-id pub-id-type="pmid">2213187</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rowe</surname><given-names>SP</given-names></name><name name-style="western"><surname>Gorin</surname><given-names>MA</given-names></name><name name-style="western"><surname>Solnes</surname><given-names>LB</given-names></name><name name-style="western"><surname>Ball</surname><given-names>MW</given-names></name><name name-style="western"><surname>Choudhary</surname><given-names>A</given-names></name><name name-style="western"><surname>Pierorazio</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Correlation of (99m)Tc-sestamibi uptake in renal masses with mitochondrial content and multi-drug resistance pump expression</article-title><source>EJNMMI Res</source><year>2017</year><volume>7</volume><fpage>80</fpage><pub-id pub-id-type="doi">10.1186/s13550-017-0329-5</pub-id><pub-id pub-id-type="pmid">28971329</pub-id><pub-id pub-id-type="pmcid">PMC5624857</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Rowe SP, Gorin MA, Solnes LB, Ball MW, Choudhary A, Pierorazio PM, et al. Correlation of (99m)Tc-sestamibi uptake in renal masses with mitochondrial content and multi-drug resistance pump expression. EJNMMI Res. 2017;7:80. 10.1186/s13550-017-0329-5.<pub-id pub-id-type="pmid">28971329</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13550-017-0329-5</pub-id><pub-id pub-id-type="pmcid">PMC5624857</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gorin</surname><given-names>MA</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>SP</given-names></name><name name-style="western"><surname>Baras</surname><given-names>AS</given-names></name><name name-style="western"><surname>Solnes</surname><given-names>LB</given-names></name><name name-style="western"><surname>Ball</surname><given-names>MW</given-names></name><name name-style="western"><surname>Pierorazio</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Prospective evaluation of (99m)Tc-sestamibi SPECT/CT for the diagnosis of renal oncocytomas and hybrid oncocytic/chromophobe tumors</article-title><source>Eur Urol</source><year>2016</year><volume>69</volume><fpage>413</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2015.08.056</pub-id><pub-id pub-id-type="pmid">26386607</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Gorin MA, Rowe SP, Baras AS, Solnes LB, Ball MW, Pierorazio PM, et al. Prospective evaluation of (99m)Tc-sestamibi SPECT/CT for the diagnosis of renal oncocytomas and hybrid oncocytic/chromophobe tumors. Eur Urol. 2016;69:413&#8211;6. 10.1016/j.eururo.2015.08.056.<pub-id pub-id-type="pmid">26386607</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eururo.2015.08.056</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rokugawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Uehara</surname><given-names>T</given-names></name><name name-style="western"><surname>Higaki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Matsushima</surname><given-names>S</given-names></name><name name-style="western"><surname>Obata</surname><given-names>A</given-names></name><name name-style="western"><surname>Arano</surname><given-names>Y</given-names></name><name name-style="western"><surname>Abe</surname><given-names>K</given-names></name></person-group><article-title>Potential of <sup>99m</sup>Tc-MIBI SPECT imaging for evaluating non-alcoholic steatohepatitis induced by methionine-choline-deficient diet in mice</article-title><source>EJNMMI Res</source><year>2014</year><volume>4</volume><fpage>57</fpage><pub-id pub-id-type="doi">10.1186/s13550-014-0057-z</pub-id><pub-id pub-id-type="pmid">26116119</pub-id><pub-id pub-id-type="pmcid">PMC4452628</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Rokugawa T, Uehara T, Higaki Y, Matsushima S, Obata A, Arano Y, Abe K. Potential of <sup>99m</sup>Tc-MIBI SPECT imaging for evaluating non-alcoholic steatohepatitis induced by methionine-choline-deficient diet in mice. EJNMMI Res. 2014;4:57. 10.1186/s13550-014-0057-z.<pub-id pub-id-type="pmid">26116119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13550-014-0057-z</pub-id><pub-id pub-id-type="pmcid">PMC4452628</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gates</surname><given-names>GF</given-names></name></person-group><article-title>Computation of glomerular filtration rate with Tc-99m DTPA: an in-house computer program</article-title><source>J Nucl Med</source><year>1984</year><volume>25</volume><fpage>613</fpage><lpage>618</lpage><pub-id pub-id-type="pmid">6374072</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Gates GF. Computation of glomerular filtration rate with Tc-99m DTPA: an in-house computer program. J Nucl Med. 1984;25:613&#8211;8.<pub-id pub-id-type="pmid">6374072</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Obert</surname><given-names>LA</given-names></name><name name-style="western"><surname>Elmore</surname><given-names>SA</given-names></name><name name-style="western"><surname>Ennulat</surname><given-names>D</given-names></name><name name-style="western"><surname>Frazier</surname><given-names>K</given-names></name></person-group><article-title>A review of specific biomarkers of chronic renal injury and their potential application in nonclinical safety assessment studies</article-title><source>Toxicol Pathol</source><year>2021</year><volume>49</volume><fpage>996</fpage><lpage>1023</lpage><pub-id pub-id-type="doi">10.1177/0192623320985045</pub-id><pub-id pub-id-type="pmid">33576319</pub-id><pub-id pub-id-type="pmcid">PMC8195817</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Obert LA, Elmore SA, Ennulat D, Frazier K. A review of specific biomarkers of chronic renal injury and their potential application in nonclinical safety assessment studies. Toxicol Pathol. 2021;49:996&#8211;1023. 10.1177/0192623320985045.<pub-id pub-id-type="pmid">33576319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0192623320985045</pub-id><pub-id pub-id-type="pmcid">PMC8195817</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pedersen</surname><given-names>SS</given-names></name><name name-style="western"><surname>Keller</surname><given-names>AK</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>MK</given-names></name><name name-style="western"><surname>Jespersen</surname><given-names>B</given-names></name><name name-style="western"><surname>Falborg</surname><given-names>L</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>JT</given-names></name><etal/></person-group><article-title>Cell injury after ischemia and reperfusion in the porcine kidney evaluated by radiolabelled microspheres, sestamibi, and lactadherin</article-title><source>EJNMMI Res</source><year>2013</year><volume>3</volume><fpage>62</fpage><pub-id pub-id-type="doi">10.1186/2191-219X-3-62</pub-id><pub-id pub-id-type="pmid">23924517</pub-id><pub-id pub-id-type="pmcid">PMC3750402</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Pedersen SS, Keller AK, Nielsen MK, Jespersen B, Falborg L, Rasmussen JT, et al. Cell injury after ischemia and reperfusion in the porcine kidney evaluated by radiolabelled microspheres, sestamibi, and lactadherin. EJNMMI Res. 2013;3:62. 10.1186/2191-219X-3-62.<pub-id pub-id-type="pmid">23924517</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/2191-219X-3-62</pub-id><pub-id pub-id-type="pmcid">PMC3750402</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fontecha-Barriuso</surname><given-names>M</given-names></name><name name-style="western"><surname>Lopez-Diaz</surname><given-names>AM</given-names></name><name name-style="western"><surname>Guerrero-Mauvecin</surname><given-names>J</given-names></name><name name-style="western"><surname>Miguel</surname><given-names>V</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>AM</given-names></name><name name-style="western"><surname>Sanchez-Ni&#241;o</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Tubular mitochondrial dysfunction, oxidative stress, and progression of chronic kidney disease</article-title><source>Antioxidants</source><year>2022</year><pub-id pub-id-type="doi">10.3390/antiox11071356</pub-id><pub-id pub-id-type="pmid">35883847</pub-id><pub-id pub-id-type="pmcid">PMC9311633</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Fontecha-Barriuso M, Lopez-Diaz AM, Guerrero-Mauvecin J, Miguel V, Ramos AM, Sanchez-Ni&#241;o MD, et al. Tubular mitochondrial dysfunction, oxidative stress, and progression of chronic kidney disease. Antioxidants. 2022. 10.3390/antiox11071356.<pub-id pub-id-type="pmid">35883847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/antiox11071356</pub-id><pub-id pub-id-type="pmcid">PMC9311633</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tirichen</surname><given-names>H</given-names></name><name name-style="western"><surname>Yaigoub</surname><given-names>H</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C</given-names></name><name name-style="western"><surname>Li</surname><given-names>R</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Mitochondrial reactive oxygen species and their contribution in chronic kidney disease progression through oxidative stress</article-title><source>Front Physiol</source><year>2021</year><volume>12</volume><fpage>627837</fpage><pub-id pub-id-type="doi">10.3389/fphys.2021.627837</pub-id><pub-id pub-id-type="pmid">33967820</pub-id><pub-id pub-id-type="pmcid">PMC8103168</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Tirichen H, Yaigoub H, Xu W, Wu C, Li R, Li Y. Mitochondrial reactive oxygen species and their contribution in chronic kidney disease progression through oxidative stress. Front Physiol. 2021;12:627837. 10.3389/fphys.2021.627837.<pub-id pub-id-type="pmid">33967820</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphys.2021.627837</pub-id><pub-id pub-id-type="pmcid">PMC8103168</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dizdarevic</surname><given-names>S</given-names></name><name name-style="western"><surname>Aplin</surname><given-names>M</given-names></name><name name-style="western"><surname>Newport</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>N</given-names></name><name name-style="western"><surname>Holt</surname><given-names>S</given-names></name><name name-style="western"><surname>Goubet</surname><given-names>S</given-names></name><etal/></person-group><article-title>Old tracer for a new purpose: potential role for <sup>99m</sup>Tc-2-Methoxyisobutylisonitrile (<sup>99m</sup>Tc-MIBI) in renal transplant care</article-title><source>Nucl Med Commun</source><year>2014</year><volume>35</volume><fpage>1058</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1097/mnm.0000000000000165</pub-id><pub-id pub-id-type="pmid">25025147</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Dizdarevic S, Aplin M, Newport MJ, Ryan N, Holt S, Goubet S, et al. Old tracer for a new purpose: potential role for <sup>99m</sup>Tc-2-Methoxyisobutylisonitrile (<sup>99m</sup>Tc-MIBI) in renal transplant care. Nucl Med Commun. 2014;35:1058&#8211;66. 10.1097/mnm.0000000000000165.<pub-id pub-id-type="pmid">25025147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MNM.0000000000000165</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>MC</given-names></name><name name-style="western"><surname>Turkington</surname><given-names>TG</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>JM</given-names></name><name name-style="western"><surname>Wong</surname><given-names>TZ</given-names></name></person-group><article-title>A systematic review of the factors affecting accuracy of SUV measurements</article-title><source>AJR Am J Roentgenol</source><year>2010</year><volume>195</volume><fpage>310</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.2214/ajr.10.4923</pub-id><pub-id pub-id-type="pmid">20651185</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol. 2010;195:310&#8211;20. 10.2214/ajr.10.4923.<pub-id pub-id-type="pmid">20651185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2214/AJR.10.4923</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>